su011248
Teratoma
Memorial Sloan Kettering Cancer CenterPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Teratoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ifosfamide Memorial Sloan Kettering Cancer Center | Phase 2 | BB |
Carboplatin Masonic Cancer Center, University of Minnesota | Phase 2 | BB |
FILGRASTIM Masonic Cancer Center, University of Minnesota | Phase 2 | BB |
ETOPOSIDE Masonic Cancer Center, University of Minnesota | Phase 3 | BB |
Thiotepa Masonic Cancer Center, University of Minnesota | Phase 2 | B |
View all 10 →
Same molecule, other indications
su011248 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →